Cancer survivor wins the lottery for a remarkable fourth time
A Canadian man has claimed a lottery jackpot for the fourth time in his life.
David Serkin's latest victory came on May 3 when he claimed $1 million in a May 3 drawing of the Lotto 6-49 Gold Ball draw in Alberta, according to a press release from the Western Canada Lottery Corporation.
This follows on from the $1 million he won in November 2024 and the $500,000 he won in August of the same year. Both victories were in the Lotto 6-49 drawing.
That brings his total winnings to $2.5 million in less than a year. His first win was a $250,000 jackpot in 2013.
'I know the odds are astronomical. I don't think it'll happen again, but I still like buying tickets.' The odds of winning the jackpot are roughly 1 in 33 million, the WCLC said.
Serkin, a resident of Lethbridge, around 130 miles south of Calgary, said that he has been purchasing lottery tickets for over 40 years.
'You check your ticket, and if you win, you're happy. If you don't, you can always try again,' he said.
He told the WCLC's website that he is a cancer survivor and is retired. 'I am just so grateful for all of it,' Serkin said.
The Lethbridge man described his recent win, saying that he was out for coffee with his sons when he checked his tickets.
When he realized he had won, 'They asked to see it and said, 'Not again!'
Serkin said that the last time he won, he took his wife, who he says is still in disbelief over his lucky streak, on a trip to Maui. This time, the couple is headed to Newfoundland for a vacation.
After his win in November, Serkin said that he was using some of his winnings to help out his friends.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Kovo+ Announces Management Change
Calgary, Alberta--(Newsfile Corp. - June 6, 2025) - Kovo+ Holdings Inc. (TSXV: KOVO) ("Kovo" or the "Company") announces that Mark Detz has resigned as Chief Financial Officer of the Company, and Kovo accepted his resignation effective as of June 4, 2024. "As a core member of senior management, Mark has been an important member of our team, and we thank him for his contributions to the Company," said Justin Anderson, Chief Executive Officer of Kovo. Following a confidential recruitment process, the Company has identified and selected a candidate to succeed Mr. Detz as Chief Financial Offer and expects to announce the appointment in due course. About Kovo+ Holdings Inc. Kovo is a versatile technology company leading the charge in AI initiatives to drive impact and innovation across diverse industries. Kovo remains committed to its core business-model of strategic growth opportunities within mid-market Medical Billing firms, where exploitative business optimization synergies exist. Moving forward, Kovo will integrate accretive broader healthcare sector additions to its portfolio and opportunities beyond in multiple new markets. Dedicated to revolutionizing business process optimization through technological advancements and evolving AI-applied methods, Kovo embodies a commitment to ensured and enduring profitability. To learn more about Kovo and to keep up to date on Kovo news, visit Cautionary Note Regarding Forward-Looking Information Statements contained in this news release that are not historical facts are "forward-looking information" or "forward-looking statements" within the meaning of applicable Canadian securities laws. Such forward-looking statements or information are provided to inform the Company's shareholders and potential investors about management's current expectations and plans relating to the future and include, but are not limited to, (i) expectations regarding the Chief Financial Officer appointment; and (ii) expectations regarding the timing and appointment thereof. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Any such forward-looking information may be identified by words such as "anticipate", "proposed", "estimates", "would", "expects", "intends", "plans", "may", "will", and similar expressions. Forward-looking statements or information are based on a number of factors and assumptions that have been used to develop such statements and information, but which may prove to be incorrect. By its nature, such forward-looking information is subject to various risks and uncertainties, which could cause the actual results and expectations to differ materially from the anticipated results or expectations expressed. Although the Company believes that the expectations reflected in such forward-looking statements or information are reasonable, undue reliance should not be placed on forward-looking statements because the Company can give no assurance that such expectations will prove to be correct. The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or expressly qualified by this cautionary statement. Contact Information For further information, please contact: investors@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Pharmaris Canada to Lead Sales and Marketing for Vimy Pharma Products Across Canada
TORONTO, ON / / June 6, 2025 / Two proudly Canadian pharmaceutical companies announced today a strategic partnership that reinforces their shared commitment to serving Canadian patients. Under the agreement, Pharmaris will assume responsibility for all sales and marketing activities for Vimy Pharma product portfolio across Canada. This landmark collaboration unites two homegrown Canadian pharmaceutical organizations, both with deep roots in the Canadian healthcare landscape. The partnership exemplifies Canadian innovation and entrepreneurship in action, while strengthening domestic pharmaceutical capabilities and expertise. Built by Canadians for Canadians, both companies have demonstrated their dedication to advancing healthcare solutions that address the unique needs of the Canadian market. This alliance further cements their shared vision of making healthcare more accessible and affordable for patients from coast to coast. "Our partnership with Vimy Pharma marks a big step forward advancing access to critical medicines for Canadians,"said Michael Sine, President of Pharmaris. "This alliance demonstrates our shared commitment to putting Canadian patients first." "We are pleased to partner with Pharmaris in broadening access to essential medicines," stated Farris Smith, President of Vimy Pharma,"as we strive to improve outcomes and make a meaningful difference to patients." ABOUT PHARMARIS CANADA Pharmaris Canada is a pharmaceutical company committed to delivering high-quality healthcare products that support the well-being of Canadians. Pharmaris Canada is part of a large diversified global group based out of Vancouver, B.C started by two pharmacists. The group has business interests spanning pharmaceuticals, residential and commercial real estate, property development, hospitality, mobility solutions, and retail pharmacy operations. Pharmaris Canada offers a distinctive portfolio of over-the-counter (OTC) and generic pharmaceutical products. Our OTC range includes a Canadian-made line of iron supplements and a broad selection of German-manufactured effervescent vitamin tablets. As one of the few companies to successfully integrate branded OTC and generic medicines, Pharmaris has developed strong capabilities in brand management, prescription navigation, and market expansion. With a presence in 16 countries and a team of 585 employees, most of whom have been with the organization for over five years, Pharmaris continues to grow its global footprint through innovation and operational excellence. ABOUT VIMY PHARMA Vimy Pharma is a Canadian pharmaceutical company committed to ensuring a stable, reliable supply of essential medicines, reducing dependence on foreign sources, and supporting good-paying jobs for Canadians in life sciences and advanced manufacturing. Our products are made to the highest standards of quality and safety, meeting rigorous Health Canada guidelines. At Vimy Pharma, our team is inspired by the groundbreaking achievements of Drs. Frederick Banting and Charles Best, and James B. Collip whose discovery in Canada of insulin revolutionized treatments and changed millions of lives worldwide. Their spirit of ingenuity, collaboration, and commitment to public health continues to guide our approach as we develop and manufacture high-quality, affordable, essential medicines for Canadian health challenges. MEDIA CONTACTMichael SinePresident, Pharmaris Canadamichael@ Farris SmithFounder & President, Vimy Pharmaceuticals - 30 - SOURCE: Pharmaris View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
Hempalta Provides Strategic Update Regarding Equipment Sale and FCC Agreement
Calgary, Alberta--(Newsfile Corp. - June 6, 2025) - Hempalta Corp. (TSXV: HEMP) ("Hempalta" or the "Company"), a Canadian-based provider of nature-based carbon credit solutions, today issued a corporate update outlining recent developments in its strategic transition. Equipment Sale Update On May 22, 2025, Hempalta announced its wholly owned subsidiary, Hempalta Processing Inc. ("HPI"), had entered into a US$1.15 million agreement to sell its hemp processing and biochar equipment (the "Transaction"). Despite follow up discussions and repeated assurances, the purchase price has not been paid to HPI; accordingly, HPI has retained ownership of all equipment and associated intellectual property and has reinitiated the asset sale process. Interested parties may contact the Company for additional details. FCC Forbearance Agreement In connection with the termination of the Transaction, HPI, has entered into a forbearance agreement with Farm Credit Canada ("FCC") dated effective June 2, 2025. This agreement extends protection through June 30, 2025, providing HPI time to complete a revised monetization plan for its processing assets while maintaining transparency and compliance with its senior lender. Carbon Credit Market Momentum Continues The Company's 2024 carbon credits now total 29,448 tonnes of CO₂ removal across 12,669 acres under the Hemp Carbon Standard. These credits are available for purchase via the Company's Cloverly storefront ( and discussions with corporate buyers are ongoing. CEO to Speak at Canadian Climate Investor Conference Hempalta President and CEO Darren Bondar will be speaking at the 2025 Canadian Climate Investor Conference hosted by the Toronto Stock Exchange (TSX and TSXV) on June 11, 2025, at the Arcadian Court in Toronto. Mr. Bondar will outline Hempalta's strategic pivot to nature-based carbon credit markets and showcase the scalable growth opportunity through its Hemp Carbon Standard platform. About Hempalta Corp. Hempalta Corp. (TSXV: HEMP) is a Canadian clean-tech company focused on high-integrity carbon removal credits derived from industrial hemp. Through its wholly owned subsidiary, Hemp Carbon Standard Inc., the Company supports regenerative agriculture, biochar deployment, and AI-powered MRV to deliver transparent, verifiable carbon credits aligned with global climate goals. Learn more at or contact Investor Relations at invest@ For more information, please contact: Investor RelationsHempalta info@ Hempalta Corp. Web: Email: info@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. Forward-Looking Information This news release contains statements and information that, to the extent they are not historical fact, may constitute "forward-looking information" within the meaning of applicable securities legislation. Forward-looking information is typically, but not always, identified by the use of words such as "expects," "plans," "continues," "intends," "anticipates," "potential," "aims," "will," and similar expressions, including negatives thereof. Forward-looking information in this news release includes, but is not limited to, statements regarding: the Company's ability to complete the sale of its hemp processing and biochar equipment; the resolution of the outstanding forbearance with Farm Credit Canada (FCC); negative cash flow from operations and the Company's ability to operate as a going concern; the anticipated proceeds and timing of any asset sales; the scaling of the Hemp Carbon Standard platform; the sale of verified carbon credits; the development of new corporate offtake agreements; and the Company's broader growth initiatives under Hempalta carbon credit platform. Such forward-looking information is based on assumptions and expectations, including but not limited to: the Company's ability to remarket and sell the equipment; continued support from major shareholders and new investors; demand for nature-based carbon removal credits; successful onboarding of additional farmers; favorable regulatory conditions; and Hempalta's ability to execute its strategic plan and secure necessary financing on reasonable terms. Although the Company believes the assumptions and expectations reflected in the forward-looking information are reasonable, undue reliance should not be placed on them, as actual results may differ materially due to known and unknown risks. These risks include, but are not limited to: economic conditions and capital market volatility; failure to close the asset sale or private placement; changes in carbon credit market demand or pricing; regulatory changes; inability to retain key personnel; weather-related challenges impacting hemp cultivation; and those risks set forth in the Company's public disclosure documents available on SEDAR+ at Forward-looking information in this news release is provided as of the date hereof, and the Company does not undertake to update such information except as required by applicable securities laws. NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER U.S. NEWSWIRES To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
